Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has announced its participation in two upcoming investor conferences.
The company will engage in webcast fireside chats at:
- UBS Virtual CNS Day on March 17, 2025, at 12:30 p.m. ET
- Stifel Virtual CNS Days on March 18, 2025, at 3:30 p.m. ET
The webcasts will be accessible through the Investors section of Acumen's website (www.acumenpharm.com) and will remain available for 90 days after the events.
Positive
- None.
Negative
- None.
News Market Reaction – ABOS
On the day this news was published, ABOS gained 5.83%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEWTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in webcast fireside chats at two upcoming investor conferences:
- UBS Virtual CNS Day on Monday, March 17, 2025, at 12:30 p.m. ET
- Stifel Virtual CNS Days on Tuesday, March 18, 2025, at 3:30 p.m. ET
The live webcasts may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When is Acumen Pharmaceuticals (ABOS) presenting at the UBS Virtual CNS Day in March 2025?
How long will the ABOS investor conference webcasts be available for viewing?
What is the focus of Acumen Pharmaceuticals' (ABOS) drug development program?
Where can investors access the ABOS March 2025 conference webcasts?
What is the schedule for ABOS's presentation at Stifel Virtual CNS Days?
